A series of pilot schemes set up by the UK in partnership with the pharma industry will test ways to get new medicines to patients more quickly. Astellas Pharma US president Percival Barretto-Ko talks ...

Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower ...

When organizers of the 1933 World’s Fair in Chicago wanted a splashy and futuristic way to kick things off on opening night, astronomer Edwin Frost of Yerkes Observatory had an idea: Turn on the ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260507780817/en/ The articles, information, and content displayed on this webpage ...

The last time I spoke about Arcturus Therapeutics Holdings Inc. (ARCT) it was with a Seeking Alpha article entitled "Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data." Regarding ...

In the preceding three months, 4 analysts have released ratings for Arcturus Therapeutics (NASDAQ:ARCT), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll ...

The company expects to initiate the 12-week Phase II ARCT-032 study in the first half of 2026, enrolling up to 20 participants and focusing on safety and early signs of clinical benefit. For ARCT-810, ...

Arcturus missed both EPS and revenue forecasts significantly. Stock price declined by 5.27% following the earnings report. Revenue declines were attributed to reduced collaboration income. The company ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110988919/en/ Arcturus Therapeutics Public Relations & Investor Relations Neda ...